[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336648-105":59,"doc-detail-336648-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unraveling-druggable-cancer-driving-proteins-and-targeted-drugs-using-artificial-intelligence-and-multi-omics-analyses","Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses","","A computational framework predicts druggable cancer-driving proteins from amino-acid sequence descriptors using 13 machine-learning classifiers, with the support vector machine performing best using 200 tri-amino acid composition features. The model achieves AUROC 0.975 ± 0.003 and accuracy 0.929 ± 0.006, validated by threefold cross-validation. Performance is boosted by multi-omics evidence, including disease-target scores, pathways to cancer hallmarks, structure-based ligandability, unfavorable prognostic analysis, and the oncogenic variome. Drug repurposing prioritizes 79 key protein targets and 11 clinically relevant drugs, enabling biomarker and trial-ready target selection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unraveling-druggable-cancer-driving-proteins-and-targeted-drugs-using-artificial-intelligence-and-multi-omics-analyses/336648/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unraveling-druggable-cancer-driving-proteins-and-targeted-drugs-using-artificial-intelligence-and-multi-omics-analyses/336648.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is druggability prediction performed in the study?","Question",{"text":112,"@type":113},"The approach trains 13 machine-learning classifiers using amino-acid composition descriptors derived from protein sequences, selecting the best-performing support vector machine model for prediction.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What metrics demonstrate the model’s predictive performance?",{"text":117,"@type":113},"The optimal classifier reports AUROC 0.975 ± 0.003 and accuracy 0.929 ± 0.006 using threefold cross-validation.",{"name":119,"@type":110,"acceptedAnswer":120},"How do multi-omics signals improve the predictions and what outcomes are produced?",{"text":121,"@type":113},"The model incorporates multi-omics evidence such as target-disease evidence scores, pathway distances to cancer hallmarks, structure-based ligandability, unfavorable prognostic protein analysis, and the oncogenic variome, leading to prioritization of 79 key proteins and 11 clinically relevant drugs for in-depth studies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336648,1790155021,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nUnraveling druggable cancer‑driving proteins and targeted drugs using artificial intelligence and multi‑omics analyses  \nAndrés López‑Cortés1*, Alejandro Cabrera‑Andrade2,3, Gabriela Echeverría‑Garcés4,5, Paulina Echeverría‑Espinoza1, Micaela Pineda‑Albán1, Nicole Elsitdie1,  \nJosé Bueno‑Miño1, Carlos M. Cruz‑Segundo6,7, Julian Dorado6,8, Alejandro Pazos6,8,9, Humberto Gonzáles‑Díaz10,11, Yunierkis Pérez‑Castillo2, Eduardo Tejera2 &  \nCristian R. Munteanu6,8,9  \nThe druggable proteome refers to proteins that can bind to small molecules with appropriate chemical affinity, inducing a favorable clinical response. Predicting druggable proteins through screening and in silico modeling is imperative for drug design. To contribute to this field, we developed an accurate predictive classifier for druggable cancer‑driving proteins using amino acid composition descriptors of protein sequences and 13 machine learning linear and non‑linear classifiers. The optimal classifier was achieved with the support vector machine method, utilizing 200 tri‑amino acid composition descriptors. The high performance of the model is evident from an area under the receiver operating characteristics (AUROC) of 0.975 ± 0.003 and an accuracy of 0.929 ± 0.006 (threefold cross‑validation) . The machine learning prediction model was enhanced with multi‑omics approaches, includingthe target‑disease evidence score, the shortest pathways to cancer hallmarks, structure‑based ligandability assessment, unfavorable prognostic protein analysis, and the oncogenic variome. Additionally, we performed a drug repurposing analysis to identify drugs with the highest affinity capable of targeting the best predicted proteins. As a result, we identified 79 key druggable cancer‑ driving proteins with the highest ligandability, and 23 of them demonstrated unfavorable prognostic significance across 16 TCGA PanCancer types: CDKN2A, BCL10, ACVR1, CASP8, JAG1, TSC1, NBN, PREX2, PPP2R1A, DNM2, VAV1, ASXL1, TPR, HRAS, BUB1B, ATG7, MARK3, SETD2, CCNE1, MUTYH, CDKN2C, RB1, and SMARCA4. Moreover, we prioritized 11 clinically relevant drugs targeting these proteins. This strategy effectively predicts and prioritizes biomarkers, therapeutic targets, and drugs for in‑depth studies in clinical trials. Scripts are available at [https://github.com/muntisa/machine](https://github.com/muntisa/machine)‑learning‑for‑druggable‑proteins.  \n1Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador. 2Grupo de Bio-Quimioinformática, Universidad de Las Américas, Quito, Ecuador. 3Escuela de Enfermería, Facultad de Ciencias de la Salud, Universidad de Las Américas, Quito, Ecuador. 4Centro de Referencia Nacional de Genómica, Secuenciación y Bioinformática, Instituto Nacional de Investigación en Salud Pública “Leopoldo Izquieta Pérez”, Quito, Ecuador. 5Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Santiago, Chile. 6RNASA-IMEDIR, Computer Science Faculty, University of ACoruna, A Coruña, Spain. 7Tecnológico de Estudios Superiores de Jocotitlán, Jocotitlán, Mexico. 8Centro de Investigación en Tecnologías de la Información y las Comunicaciones (CITIC), University of A Coruna, A Coruña, Spain. 9Biomedical Research Institute of A Coruna (INIBIC), University Hospital Complex of A Coruna (CHUAC), A Coruña, Spain. 10Department of Organic Chemistry II, University of the Basque Country UPV/EHU, Biscay,  \nSpain. 11IKERBASQUE, Basque Foundation for Science, Biscay, Spain. * email: [aalc84@gmail.com](aalc84@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nThe human genome comprises approximately 19,890 protein-coding genes, yet not all these proteins serve as suitable drug targets1–3. The druggable proteome refers to the subset of proteins capable of binding to an antibody or small molecule with the","cbCaigeMcdyeTg0A","https://ap.wps.com/l/cbCaigeMcdyeTg0A","pdf",7249791,22,"English","# Overview\n## Prediction model based on protein sequence descriptors\n## Model performance and validation\n## Multi-omics enhancements\n## Drug repurposing and prioritized targets","[{\"question\":\"How is druggability prediction performed in the study?\",\"answer\":\"The approach trains 13 machine-learning classifiers using amino-acid composition descriptors derived from protein sequences, selecting the best-performing support vector machine model for prediction.\"},{\"question\":\"What metrics demonstrate the model’s predictive performance?\",\"answer\":\"The optimal classifier reports AUROC 0.975 ± 0.003 and accuracy 0.929 ± 0.006 using threefold cross-validation.\"},{\"question\":\"How do multi-omics signals improve the predictions and what outcomes are produced?\",\"answer\":\"The model incorporates multi-omics evidence such as target-disease evidence scores, pathway distances to cancer hallmarks, structure-based ligandability, unfavorable prognostic protein analysis, and the oncogenic variome, leading to prioritization of 79 key proteins and 11 clinically relevant drugs for in-depth studies.\"}]","Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses | PDF",1790016015,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dd1a1e9ac586a1dad8b8c3557611d8d.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b44793ccf9cbfe123da83d9e68a4b8f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3592b02d8900fcb1608419a36bf5cf48.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0f1860f600f932359939d9820904949.webp",980,1287]